How To Sell One Molecule Two Ways And Make Billions

Did you know Novo Nordisk’s (NVO) Ozempic and Wegovy are basically twins separated at birth?

Both contain the same molecule — semaglutide — yet Wegovy costs three times more simply because it moonlights as a weight-loss drug instead of a diabetes treatment.

That, my friends, is pharmaceutical sorcery so profitable it would make Merlin jealous.

And yet, despite sitting on what might be the most lucrative molecule since Pfizer’s (PFE) little blue pill rewrote bedroom history, Novo’s stock has taken a noticeable hit.

Timing, as they say, is everything. And sometimes, the market’s sense of timing is like a GPS with a dead battery: lost and confused.

While others were looking elsewhere, I’ve kept a close eye on this Danish giant. Contrarian? Maybe.

But when a company revolutionizing chronic disease care for 46 million patients starts trading at a discount to its peers, it certainly earns a place on my watchlist.

Let’s talk numbers. Novo’s Q1 FY2025 earnings came in strong: $11.8 billion in revenue, up 25.84% year-over-year, and earnings of $0.99 a share, up 20.7%. And yes, they crushed Wall Street’s expectations with a 6.88% earnings surprise.

The real fireworks, though, are in their Obesity Care segment, where Wegovy sales popped 65%.

Even the dependable Diabetes Care unit — think Ozempic and Rybelsus — clocked in with a healthy 11% gain.

This isn’t just steady growth. It’s exponential, global-scale, paradigm-shifting growth. In biotech terms, that’s like finding penicillin in your lunchbox.

Sure, there are clouds. The specter of compounded GLP-1 products has been eating into Novo’s market share like termites in a wooden house.

These copycat versions, often sold at lower prices, gained a foothold when branded Wegovy and Ozempic were on the FDA’s drug shortage list. It’s the pharmaceutical equivalent of knockoff Rolex watches flooding the market when the real Swiss timepieces are backordered.

But the party’s over. As of February 2025, semaglutide is off the shortage list, and compounding pharmacies are legally benched unless it’s an emergency.

Novo’s not playing defense either. They’ve rolled out a direct-to-patient program with Wegovy at $499 a month — and a tasty $199 for first-timers.

They’re also teaming up with telehealth players like Hims & Hers Health (HIMS) and LifeMD (LFMD), expanding access faster than its competitors.

Then there’s CVS (CVS), the 800-pound gorilla of pharmacy benefits, naming Wegovy the only obesity drug on its national formulary come July 1. That’s not just market share — that’s an exclusive VIP section with velvet ropes.

As for political bogeymen, President Trump’s “Most Favored Nation” pricing order looms, but enforcement looks about as aggressive as a paper tiger.

U.S. cash-pay pricing sits at $499, Denmark at $350, and the UK around $270 — not exactly the stuff of pricing scandals.

Here’s where the rubber meets the road. Assuming a conservative 45% EBITDA margin, which is below their trailing 50.5%, Novo could post $26.48 billion in EBITDA.

Slap a modest 15x EV/EBITDA multiple on that for FY2026, subtract $11.19 billion in net debt, and you’re looking at more than 15% upside. Not bad for a “boring” drugmaker, eh?

And let’s not forget, this isn’t just any drugmaker. The global GLP-1 receptor agonist market is projected to hit $268.37 billion by 2034, expanding at a 17.5% compound annual growth rate.

Those are technology-sector-like growth rates in a healthcare setting.

With a CEO transition looming — always a potential wildcard in PharmaLand — Novo keeps the dividends flowing, currently yielding around 2.52%, with more hikes likely.

Oh, and they’re trading at about half the EV/EBITDA multiple of Eli Lilly (LLY). You do the math.

Novo Nordisk is what I call a stealth juggernaut: undervalued, misunderstood, and quietly gobbling market share while the crowd is distracted. It’s an opportunity gift-wrapped by market myopia. I suggest you buy the dip with both hands.